Taken together, our research is the first to identify that focal adhesion kinase inhibitor BI853520 inhibits cell proliferation, migration and EMT process through PI3K/AKT/mTOR signaling pathway in ovarian cancer. This evidence concerns the gene AKT1 and ovarian cancer.